Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RPTR-168 in HPV-16+ Tumors and Melanoma
NCT04762225Phase 1Terminated
- Sponsor
- Repertoire Immune Medicines
- Start
- May 2021
- Primary completion
- Sep 2022
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RPTR-168 in head and neck squamous cell carcinoma (HNSCC), Cervical Cancer (CC), melanoma and 3 more, sponsored by Repertoire Immune Medicines. Primary endpoints: Number of subjects with Dose Limiting Toxicities at 28 days and Frequency of dose interruptions at 28 days. Started May 2021; status: terminated.
02
Drugs
RPTR-168
03
Conditions
head and neck squamous cell carcinoma (HNSCC)Cervical Cancer (CC)melanomaanal cancerpenile cancer
Beyond the preview
Go deeper on NCT04762225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04762225.